Gencor launched VeriSperse, a cold-water dispersible resveratrol powder featuring Veri-te.
Gencor (Irvine, CA) launched VeriSperse, a cold-water dispersible resveratrol powder featuring Veri-te, a clinically studied resveratrol manufactured by Evolva (Reinach, Switzerland), and LipiSperse, an enhanced dispersion technology designed by Pharmako that increases bioavailability of resveratrol two to three times greater. The LipiSperse technology in VeriSperse creates a repulsion between the powder surface of the ingredient and solution to establish equilibrium to prevent agglomeration or aggregation, for easy dispersion in water. This provides greater absorption and efficacy of resveratrol.
“Given Veri-te’s recently published outcomes in the journal Menopause, we feel even more confident in the ability of the resveratrol to address critical life markers and symptoms for menopausal women.” said Chase Shyroc, vice president of sales and business development for Gencor, in a press release. “In marrying Veri-te and LipiSperse technologies, Veri-Sperse provides a superior resveratrol that can be applied in limitless applications to support healthy aging and improved quality of life for women suffering the symptoms of menopause.”
Veri-te resveratrol was the focal point of RESHAW, a double-blind, placebo-controlled study that examined the impact of the resveratrol on post-menopausal women. In addition to improving quality of life for post-menopausal women, the RESHAW study also found that resveratrol may attenuate the decline in cognitive function in postmenopausal women.